Stockscreener 앱 받기
0.352
1.29%
-0.0039
전일 마감가:
$0.3559
열려 있는:
$0.364
하루 거래량:
1.51M
Relative Volume:
0.21
시가총액:
$51.63M
수익:
$49.09M
순이익/손실:
$-52.15M
주가수익비율:
-0.5415
EPS:
-0.65
순현금흐름:
$-45.93M
1주 성능:
+16.63%
1개월 성능:
-29.06%
6개월 성능:
-72.55%
1년 성능:
-75.09%
1일 변동 폭
$0.34
$0.367
1주일 범위
$0.2541
$0.5147
52주 변동 폭
$0.1718
$2.04
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
BDSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.3523 | 32.24M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
391.68 | 152.86B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
183.81 | 136.66B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
497.10 | 41.18B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
107.14 | 32.05B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
135.19 | 24.29B | 15.50B | 1.33B | 2.16B | 7.34 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting | BDSX Stock News - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - GlobeNewswire
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award - GlobeNewswire
Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Craig-Hallum Adjusts Price Target for Biodesix (BDSX) | BDSX Sto - GuruFocus
Diagnostic Leader Biodesix Clinches Elite Colorado Workplace Award, Employee Survey Reveals Why - Stock Titan
Biodesix stock plunges as life-sciences firm cuts sales projection - BizWest
Biodesix (BDSX): Analyst Maintains Buy Rating Despite Lowered Pr - GuruFocus
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BD - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating By Investing.com - Investing.com Nigeria
Biodesix stock target cut to $2 by TD Cowen, retains buy rating - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BDSX Stock News - GuruFocus
Biodesix Inc Reports Q1 2025 Earnings: EPS of -$0.08 Misses Esti - GuruFocus
Biodesix stock rating cut to Market Perform at William Blair By Investing.com - Investing.com South Africa
BDSX: Canaccord Genuity Lowers Price Target for Biodesix | BDSX Stock News - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating - Investing.com Australia
BDSX Reports Q1 Revenue Below Expectations, Highlights Strategic - GuruFocus
Biodesix price target lowered to $1.50 from $2.50 at Canaccord - TipRanks
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Dec - GuruFocus
Biodesix price target lowered to $1.50 from $3 at Craig-Hallum - TipRanks
Biodesix price target lowered to $2 from $3 at TD Cowen - TipRanks
Biodesix (BDSX) Downgraded to Market Perform by William Blair | - GuruFocus
Biodesix (BDSX) Target Price Reduced to $2 Amid Revenue Challeng - GuruFocus
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Declines | BDSX Stock News - GuruFocus
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.12%
0.58%
자본화:
|
볼륨(24시간):